日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism

乌帕卡塞：一种用于治疗继发性甲状旁腺功能亢进症血液透析患者的新型静脉注射拟钙剂

期刊:
影响因子:
doi:10.1002/1744-9987.70126
Koiwa, Fumihiko; Honda, Daisuke; Akari, Seigo; Akizawa, Tadao
发表日期：2026
文献求助 收藏

Association of serum phosphate levels and statin use with cardiovascular events in Japanese patients on chronic haemodialysis: a post-hoc analysis of the LANDMARK trial

血清磷酸盐水平和使用他汀类药物与日本慢性血液透析患者心血管事件的相关性：LANDMARK试验的事后分析

期刊:Clinical Kidney Journal
影响因子:4.6
doi:10.1093/ckj/sfaf151
Saito, Tomohiro; Mizobuchi, Masahide; Yamakawa, Akane; Kagimura, Tatsuo; Ogata, Hiroaki; Fukagawa, Masafumi; Hirakata, Hideki; Akizawa, Tadao; Honda, Hirokazu
发表日期：2025
文献求助 收藏

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study

乌帕卡塞治疗日本血液透析继发性甲状旁腺功能亢进患者的长期疗效和安全性：一项为期 52 周的开放标签研究

期刊:American Journal of Nephrology
影响因子:3.2
doi:10.1159/000541493
Hamano, Takayuki; Koiwa, Fumihiko; Isaka, Yoshitaka; Yokoyama, Keitaro; Fukagawa, Masafumi; Inagaki, Yosuke; Watanabe, Yukihisa S; Honda, Daisuke; Akizawa, Tadao
发表日期：2025
文献求助 收藏

Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia

替那帕诺：一种用于治疗透析患者高磷血症的新型治疗药物

期刊:
影响因子:
doi:10.1111/1744-9987.14241
Akizawa, Tadao; Urano, Natsuki; Ikejiri, Kazuaki; Nakanishi, Kaoru; Fukagawa, Masafumi
发表日期：2025
文献求助 收藏

Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan

透析依赖型慢性肾病患者血栓栓塞事件的危险因素：日本罗沙司他3期临床试验的汇总分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02727-3
Hamano, Takayuki; Yamaguchi, Yusuke; Goto, Kashia; Mizokawa, Sho; Ito, Yuichiro; Dellanna, Frank; Barratt, Jonathan; Akizawa, Tadao
心血管
发表日期：2024
文献求助 收藏

Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials

透析依赖型慢性肾病患者血栓栓塞事件的危险因素：四项全球罗沙司他3期试验的汇总分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02728-2
Hamano, Takayuki; Yamaguchi, Yusuke; Goto, Kashia; Martin, Shaka; Jiletcovici, Alina; Dellanna, Frank; Akizawa, Tadao; Barratt, Jonathan
心血管
发表日期：2024
文献求助 收藏

Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies

罗沙司他治疗腹膜透析患者的疗效和安全性：四项 3 期研究的汇总分析

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm13226729
Fliser, Danilo; Bhandari, Sunil; Ortiz, Alberto; Santos, Vicki; Khalife, Najib; Jiletcovici, Alina; Akizawa, Tadao
发表日期：2024
文献求助 收藏

Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling

日本医生和患者对慢性肾脏病相关贫血治疗的偏好：一项包含最佳-最差等级的调查

期刊:Patient Preference and Adherence
影响因子:2
doi:10.2147/PPA.S450464
Mishina, Sari; Ito, Yuichiro; Lee, Takumi; Murofushi, Toshiaki; Uetake, Yoshiyuki; Akizawa, Tadao
贫血
代谢
发表日期：2024
文献求助 收藏

Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial

替那帕诺用于治疗伴有高磷血症的腹膜透析患者：一项3期试验

期刊:Clinical and Experimental Nephrology
影响因子:1.7
doi:10.1007/s10157-023-02406-1
Nakayama, Masaaki; Kobayashi, Shuhei; Kusakabe, Miho; Ohara, Meiko; Nakanishi, Kaoru; Akizawa, Tadao; Fukagawa, Masafumi
发表日期：2024
文献求助 收藏

Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study

NRF2多态性对巴多索隆甲酯安全性和有效性的影响：TSUBAKI研究的亚组分析

期刊:Clinical and Experimental Nephrology
影响因子:1.7
doi:10.1007/s10157-023-02427-w
Ikejiri, Kazuaki; Suzuki, Takafumi; Muto, Satsuki; Takama, Hirotaka; Yamawaki, Kengo; Miyazawa, Tatsuya; Urakawa, Itaru; Aoki, Yuichi; Otsuki, Akihito; Katsuoka, Fumiki; Kinoshita, Kengo; Nangaku, Masaomi; Akizawa, Tadao; Yamamoto, Masayuki
BAK
NRF2
发表日期：2024
文献求助 收藏